- Home
- LCTX vs LPAA Comparison
LCTX vs LPAA Comparison
Compare LCTX & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- LPAA
- Stock Information
- Founded
- LCTX 1990
- LPAA 2024
- Country
- LCTX United States
- LPAA United States
- Employees
- LCTX N/A
- LPAA N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- LPAA
- Sector
- LCTX Health Care
- LPAA
- Exchange
- LCTX Nasdaq
- LPAA Nasdaq
- Market Cap
- LCTX 274.0M
- LPAA 299.3M
- IPO Year
- LCTX N/A
- LPAA 2024
- Fundamental
- Price
- LCTX $1.44
- LPAA $10.49
- Analyst Decision
- LCTX Strong Buy
- LPAA
- Analyst Count
- LCTX 4
- LPAA 0
- Target Price
- LCTX $4.25
- LPAA N/A
- AVG Volume (30 Days)
- LCTX 1.2M
- LPAA 7.3K
- Earning Date
- LCTX 11-13-2025
- LPAA 01-01-0001
- Dividend Yield
- LCTX N/A
- LPAA N/A
- EPS Growth
- LCTX N/A
- LPAA N/A
- EPS
- LCTX N/A
- LPAA 0.35
- Revenue
- LCTX $10,914,000.00
- LPAA N/A
- Revenue This Year
- LCTX N/A
- LPAA N/A
- Revenue Next Year
- LCTX $176.00
- LPAA N/A
- P/E Ratio
- LCTX N/A
- LPAA $29.70
- Revenue Growth
- LCTX 76.43
- LPAA N/A
- 52 Week Low
- LCTX $0.37
- LPAA $9.96
- 52 Week High
- LCTX $1.42
- LPAA $10.70
- Technical
- Relative Strength Index (RSI)
- LCTX 69.73
- LPAA 68.72
- Support Level
- LCTX $1.20
- LPAA $10.43
- Resistance Level
- LCTX $1.42
- LPAA $10.50
- Average True Range (ATR)
- LCTX 0.07
- LPAA 0.01
- MACD
- LCTX 0.01
- LPAA 0.00
- Stochastic Oscillator
- LCTX 91.67
- LPAA 85.71
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.